Personalis Announces Launch of Public Offering of Common Stock
27 1월 2021 - 6:31AM
Business Wire
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics
for population sequencing and cancer, today announced that it has
commenced an underwritten public offering of $150.0 million of its
common stock. In addition, Personalis expects to grant the
underwriters a 30-day option to purchase up to an additional $22.5
million of common stock on the same terms and conditions.
The offering is subject to market conditions, and there can be
no assurance as to whether or when the offering may be completed or
as to the actual size or terms of the offering.
Morgan Stanley, BofA Securities, Citigroup and Cowen are acting
as joint book-running managers. BTIG is acting as co-manager.
A shelf registration statement relating to the shares being sold
in this offering was filed with the U.S. Securities and Exchange
Commission on December 30, 2020, and was declared effective on
January 8, 2021. The offering will be made only by means of a
prospectus supplement and accompanying prospectus. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering have been filed with the SEC and are available for free on
the SEC’s website located at http://www.sec.gov. When available,
electronic copies of the preliminary prospectus supplement and
accompanying prospectus relating to the proposed public offering
may be obtained from Morgan Stanley & Co. LLC, Attention:
Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY
10014; BofA Securities, Attention: Prospectus Department,
NC1‐004‐03‐43, 200 North College Street, 3rd floor, Charlotte, NC
28255‐0001, or by emailing dg.prospectus_requests@bofa.com;
Citigroup Global Markets Inc., c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at
1-800-831-9146; or Cowen and Company, LLC, c/o Broadridge Financial
Solutions, Attention: Prospectus Department, 1155 Long Island
Avenue, Edgewood, NY 11717, telephone: 1-833-297-2926.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer
genomics, with a focus on data, scale, efficiency and quality.
Personalis operates one of the largest sequencing programs globally
and is currently the sole sequencing provider to the U.S.
Department of Veterans Affairs Million Veterans Program. In
oncology, Personalis is transforming the development of
next-generation therapies by providing more comprehensive molecular
data about each patient’s cancer and immune response. The
Personalis® ImmunoID NeXT Platform® is designed to adapt to the
complex and evolving understanding of cancer, providing its
biopharmaceutical customers with information on all of the
approximately 20,000 human genes, together with the immune system,
from a single tissue or blood sample. The Personalis® Clinical
Laboratory is GxP aligned as well as CLIA’88-certified and
CAP-accredited.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements relating to Personalis’ expectations regarding
the proposed public offering. These statements are subject to
significant risks and uncertainties and actual results could differ
materially from those projected. Personalis cautions investors not
to place undue reliance on the forward-looking statements contained
in this release. These risks and uncertainties include, without
limitation, risks and uncertainties related to market conditions,
the risk that the proposed public offering will not be consummated
on the terms or in the amounts contemplated or otherwise, and the
satisfaction of customary closing conditions related to the
proposed public offering. Risks and uncertainties relating to
Personalis and its business can be found in the “Risk Factors”
sections of Personalis’ Form 10-Q for the quarter ended September
30, 2020, filed with the SEC on November 5, 2020, the self
registration statement filed with the SEC on December 30, 2020 and
the preliminary prospectus supplement related to the proposed
public offering filed with the SEC on January 26, 2021. Personalis
undertakes no duty or obligation to update any forward-looking
statements contained in this release as a result of new
information, future events or changes in Personalis’ expectations,
except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210126006088/en/
Investor Relations Contact for Personalis: Caroline
Corner investors@personalis.com www.westwicke.com
415-202-5678
Media Contact for Personalis: Jennifer Havlek
pr@personalis.com www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024